05.19.26 -- Mastering Biotech's Insourcing/Outsourcing Trade-Offs

Delve into the specific advantages of dual-sourcing in pharmaceutical fill/finish, as well as how this approach can bolster supply chain resilience, increase capacity, and accelerate commercialization.

By leveraging cells equipped with an existing landing pad, we demonstrate how inducible expression can be efficiently achieved within just 4-6 weeks after donor plasmid creation.

A strategic framework outlines ten critical questions to evaluate a manufacturing partner’s reliability, expertise, performance, and operational rigor to ensure successful, scalable cell‑therapy development.

Establishing unified component standards through collaborative innovation eliminates unnecessary investment, reduces development timelines, and ensures scalable, patient-centered delivery systems.

Particle counts don’t manage risk. Biologics need particle ID and forensic insight to separate benign artifacts from real threats and guide early decisions.

Understanding the obstacles you may face during bioconjugate development, as well as the tools available to help overcome them, can help streamline your product’s path to market.

Antibody–drug conjugates link antibodies to potent toxins, but increased hydrophobicity impairs stability, manufacturing, and PK, spurring interest in hydrophilic linker strategies.

See how higher API activity is changing expectations around containment, scalability, and cross‑functional alignment — and why early decisions now have a greater impact on long‑term success.

A novel valve provides dual‑chamber functionality within standard syringes, keeping two liquid drugs separated until injection while reducing development risk through advanced modeling.

Standardized, continuously optimized facility design enables scalable and reliable biomanufacturing that improves quality, accelerates timelines, and ensures consistent performance across sites.

Complex biologics require flexible development, advanced analytics, and quality by design. Learn how collaborative bioprocessing reduces risk, enables efficient scale‑up, and supports clinical success.

In our series on pre-filled syringes, we explore five key ways this delivery format is enhancing patient outcomes, not just through the medicine it contains, but through the device design itself.

Explore the benefits of using mRNA for vaccines and therapeutics, and learn how to address technical, intellectual property, and cost considerations when considering commercial production.